Key result
Intracoronary TAFI levels were significantly higher in patients with coronary artery disease compared to controls, suggesting TAFI may be a risk factor for CAD development.
Why the study?
Are TAFI antigen levels associated with the presence of coronary artery disease in patients undergoing angiography?
Case-Control (n=496)
Are TAFI antigen levels associated with the presence of coronary artery disease in patients undergoing angiography?
Answers are grounded in this paper and cite their sources.
Elevated intracoronary TAFI levels are associated with the presence of coronary artery disease, suggesting a potential role in inflammation and CAD development.
Due to its role in the balance between coagulation and fibrinolysis, thrombin activatable fibrinolysis inhibitor (TAFI) may be involved in the development of cardiovascular diseases. We studied 362 patients with coronary artery disease (CAD) and 134 control subjects free of CAD, both groups investigated by angiography. TAFI antigen levels were determined in venous and intracoronary plasma samples and were related to metabolic and hemostatic risk factors and extent of coronary atherosclerosis. Venous TAFI levels tended to be higher in CAD patients compared to controls, whereas this difference was significant in intracoronary samples. A subgroup of patients who had not experienced acute myocardial infarction or undergone previous cardiac interventions showed significantly higher TAFI levels in both venous and intracoronary plasma samples. TAFI levels correlated with acute phase reactants indicating a role for TAFI in inflammation. However, TAFI levels did not correlate with extent of coronary atherosclerosis and among the classical cardiovascular risk factors TAFI levels only correlated with total cholesterol and fibrinogen concentration. Our results suggest that TAFI might be a risk factor for the development of CAD.
No takes yet. Share an insight, caveat, or question.
Schroeder et al. (2002) conducted a case-control in Coronary artery disease (n=496). Thrombin Activatable Fibrinolysis Inhibitor (TAFI) levels vs. Control subjects free of CAD was evaluated on TAFI antigen levels in venous and intracoronary plasma samples. Intracoronary TAFI levels were significantly higher in patients with coronary artery disease compared to controls, suggesting TAFI may be a risk factor for CAD development.
Synapse has enriched 10 related papers. Consider them for comparative context: